Trial · NCT00086190
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Hamilton Depression Rating Scale (HAM-D) Scores | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. |
| Secondary | Change in Montgomery-Asberg Depression Rating Scale (MADRS) | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. |
| Secondary | Change in Beck Depression Inventory II (BDI-II) | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. |
| Secondary | Change in Geriatric Depression Rating Scale (GDS) | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. |
| Secondary | Change in Brief Psychiatric Rating Scale (BPRS) | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. |
| Secondary | Change in Unified Parkinson's Disease Rating Scale (UPDRS) | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. |
| Secondary | Change in Snaith Clinical Anxiety Scale (CAS) | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. |
| Secondary | Change in Pittsburgh Sleep Quality Index (PSQI) | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. |
| Secondary | Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Motor | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. |
| Secondary | Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Tremor | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. |
| Secondary | Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Bulbar | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. |
| Secondary | Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Overall | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. |
| Secondary | Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Emotional Well-Being | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. |
| Secondary | Change in Short Form 36 Health Survey - Mental Component Summary | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. |
| Secondary | Change in Short Form 36 Health Survey - Vitality | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. |
| Secondary | Change in Short Form 36 Health Survey - Role-Emotional | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. |
| Secondary | Change in Short Form 36 Health Survey - Mental Health | from the beginning (0 weeks) to end (12 weeks) of the double-blind phase | Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00086190/registered